articleThe Lancet OncologyJul 22, 2019Closed access

Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study

CRCaroline RobertARAntoni RibasJSJacob SchachterAAAna AranceJGJean‐Jacques Grob

Institut Gustave Roussy · Université Paris-Sud · +24 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

1,146
total citations
FWCI
65.97
Percentile
100%
References
33
Citations per year

Authors

20

Topics & keywords

Topics
Keywords
  • Ipilimumab
  • Pembrolizumab
  • Post-hoc analysis
  • Open label
  • Medicine
  • Post hoc
  • Oncology
  • Internal medicine
No related works found for this paper.

Funding